Navigation Links
Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
Date:2/10/2010

atumomab in pediatric ALL – Based on experience from compassionate use utilization of blinatumomab in pediatric patients with relapsed/refractory ALL, the efficacy results in adult ALL and preliminary discussions with the EMEA, the Company is in the process of designing studies to facilitate expedited development of blinatumomab in this setting. The Company expects to finalize discussions with FDA and EMEA regarding its registration strategy in pediatric ALL during the course of 2010.

"Children resistant to available treatments for ALL are in dire need of new therapeutic options," said Arend von Stackelberg, M.D., Pediatric Oncology/Hemotology, Charite - University Clinic, Berlin, Germany.  "The experience to date with blinatumomab in ALL is very encouraging and provides a strong rationale for expanded development in the pediatric setting."

  • Phase 2 study in relapsed/refractory adult ALL – The Company plans to initiate an exploratory Phase 2 single-arm study in adult patients with relapsed/refractory ALL.  The primary endpoint of the study is hematological complete response rate.  The Company currently expects to initiate the study in mid-2010.

"Many adults with ALL who achieve complete remission will eventually relapse, making prevention of recurrence the best strategy for long-term patient survival," said Deborah Thomas, M.D., Associate Professor, Department of Leukemia, MD Anderson Cancer Center, Houston, Texas.  "Novel therapeutic approaches for the treatment of this disease are therefore desperately needed."

  • Phase 2 study in relapsed/refractory Chronic Lymphocytic Leukemia (CLL) – In collaboration with leading investigator
    '/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
2. Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
3. Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009
4. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
7. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
8. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
9. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
10. Micromet Key Events for 2009
11. Micromet Expands Committed Equity Financing Facility to $75 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  For Cloud Pharmaceuticals, Inc., ... and development, partnering is an integral part of ... design new drugs and identify early stage, preclinical, ... further their development. The company also partners with ... this business model, Cloud Pharmaceuticals will be participating ...
(Date:9/19/2014)... 2014  Diplomat, the nation,s largest independent specialty pharmacy, ... to the Board of Directors on September 15, 2014. ... serve as chair of the Audit Committee. ... financial, compliance and operating experience in the health care ... chief financial officer, chief operating officer and secretary of ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... SPRING, Md., March 30 The Laboratory Response Network ... public in health emergencies, will mark its first decade ... 2009.Founded in 1999 by the Association of Public Health ... (CDC) and the Federal Bureau of Investigation (FBI) to ...
... 29 Results from a new sub-,analysis of ... to normal,cholesterol levels and elevated high sensitivity C-reactive ... LDL-C <70mg/dL and hsCRP <2mg/L with,CRESTOR(R) (rosuvastatin calcium) ... to placebo than those who did not (65% ...
Cached Medicine Technology:Nation's Laboratory Response Network Marks First Decade of Protecting Public Health 2CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis 2CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis 3CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis 4
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... patients burdened by stress and family conflicts before surgery ... operation, a new study suggests. Investigators found that ... a nearly three times greater risk for complications compared ... life. "We,ve long known that patient quality of ...
(Date:9/19/2014)... using intact cells to treat and cure disease ... it is hindered by the inability of doctors and ... of these cells in patients without resorting to invasive ... September 17 in the online journal Magnetic Resonance ... San Diego School of Medicine, University of Pittsburgh and ...
(Date:9/19/2014)... --- Domestic violence occurs at least as frequently, ... compared to opposite-sex couples, according to a review ... , Previous studies, when analyzed together, indicate that ... of lesbian, gay and bisexual individuals. However, a ... paints an incomplete picture of the true landscape, ...
(Date:9/19/2014)... (PRWEB) September 20, 2014 As summer vacations ... DMD in Queens, NY now reminds area patients about the ... 80% of our population affected by gum disease, there is ... , For over 20 years Dr. Krishnan has treated patients ... office location. “Most patients that come in due to common ...
(Date:9/19/2014)... M.D., a second-year resident in the Department of ... Medicine and Health Sciences, received at $154K grant ... presence of diffuse brain swelling and injury in ... epidemiological studies, intracerebral hemorrhage accounts for less than ... least treatable form of stroke, with the highest ...
Breaking Medicine News(10 mins):Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:A better way to track emerging cell therapies using MRIs 2Health News:Domestic violence likely more frequent for same-sex couples 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2
... use of designated drivers and open dialogue between parents ... ... Attorney General Bob,McDonnell today launched a campaign aimed at preventing drunk driving ... on stations throughout the state. The spots are timed to,coincide with the ...
... Third ... Straight Year, FLINT, Mich., Oct. 26 ... Medicaid health,plans have been recognized by U.S. News & World Report as ... top 50,Commercial plans and the top 25 plans for both Medicare and ...
... website allows consumers to share experiences on anti-aging and ... ... ( http://www.realself.com ),today announced the public launch of the first consumer ... lifestyle choices. On RealSelf.com, consumers engage in an,open and honest conversation ...
... Help End Insurance Coverage Exclusions for,Pre-existing Conditions for ... The National Patient,Advocate Foundation (NPAF) -- a ... avenues of improved patient access to health,care through ... levels -- today,praised Senator Jay Rockefeller (D-WV) for ...
... 26 Uroplasty, Inc. (Amex:,UPI) announced today that ... of fiscal 2008 ended September 30, 2007, before ... Company will host a conference call to,discuss these ... a.m. Central,Time. David Kaysen, President and Chief Executive ...
... YORK, Oct. 26 American Oriental,Bioengineering, Inc. (NYSE: ... of,plant-based pharmaceutical and nutraceutical products in China, today,announced ... in,November. The Company will present at the ... November 6, 2007 at the Waldorf-Astoria,Hotel in New ...
Cached Medicine News:Health News:Virginia Attorney General Addresses Drunk Driving and Underage Drinking in New Radio Campaign 2Health News:Consumers Open Up on RealSelf.com About 'Getting Work Done' 2Health News:Consumers Open Up on RealSelf.com About 'Getting Work Done' 3Health News:National Patient Advocate Foundation Hails Senator Rockefeller for Introducing Bill Protecting Patient Access to Health Coverage 2Health News:American Oriental Bioengineering Announces Participation in November Healthcare Conferences 2
Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-96 Myeloperoxidase...
... the quantitative determination of Immunoglobulin E ... atopic allergic diseases such as atopic ... been shown to exhibit increased total,immunoglobulin ... is also known as the,reagenic antibody. ...
... Immune Complexes from patient serum or plasma, standards ... onto microtiter wells. After a washing step, ... binds to the Fc region of human IgG. ... is pipetted followed by a stopping step. ...
... Images captured with the CR-DGi can be viewed ... just the beginning. Because the images are ... applications, such as telemedicine and electronic filing. ... with quality and ease of use. It's the ...
Medicine Products: